-
Oct 18, 2021
Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program
Read more
-
Apr 29, 2021
Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast Surgeons
Read more
-
Dec 14, 2020
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
Read more
-
Aug 04, 2020
Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer Surgery
Read more
-
Feb 26, 2020
Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020
Read more
-
Nov 22, 2019
Avelas Welcomes Susan Stimson to its Board of Directors
Read more
-
Jun 17, 2019
Avelas Biosciences Selected as a 2019 Showcase Company by MedTech Innovator
Read more
-
Mar 04, 2019
Avelas Biosciences Grows Management Team
Read more
-
Dec 04, 2018
Avelas Biosciences Presents Phase II, Period 1 Data in Poster Session at San Antonio Breast Cancer Symposium
Read more
Next Page »
